Serum p53 antibodies in correlation to other biological parameters of breast cancer

Sangrajrang, Suleeporn; Arpornwirat, Wichit; Cheirsilpa, Arkom; Thisuphakorn, P; Kalalak, Anant; Sornprom, Adisak; Soussi, Thierry

doi:10.1016/s0361-090x(03)00066-7

Cited by 22 publications

(36 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, p53 expression was associated with tumor proliferation, indicating that p53 accumulation may confer a proliferative advantage for gastrointestinal cells, in correspondence with other malignancies in breast (Sangrajrang et al 2003) and prostate (Capello et al 2006).…”

Section: Discussionsupporting

confidence: 63%

“…p53 is the most commonly mutated gene in human tumors (Takahashi et al 1998;Maehara et al 1999;Saito et al 1999;Okuyama et al 2002;Sangrajrang et al 2003;Capello et al 2006;Guan et al 2006;Mattioli et al 2007;Qiu et al 2007). The p53 family plays an important role in gastrointestinal malignancies (Guan et al 2006).…”

Section: Introductionmentioning

confidence: 99%

“…It is known that p53 acts as a key cell cycle regulator in response to stress signals, either by inducing cell growth arrest, senescence or apoptosis (Maeda et al 1998a;Takahashi et al 1998;McLeod and Murray 1999;Maehara et al 2000Maehara et al , 2001Lanz et al 2002;Constantinou et al 2003;Fenoglio-Preiser et al 2003;Sangrajrang et al 2003;Guan et al 2006). Moreover, it has been suggested that p53 prevent the growth of potential tumor cells related to its function as a tumor suppressor gene (Haupt et al 2002;Nayak and Das 2002).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

Montero

Abreu

Tonino

2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

Montero

Abreu

Tonino

2007

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…This discovery did not attract much attention until recently. The clinical significance of serum p53 Abs in cancer patients has been studied during the past few years in a large number of sera from patients with various malignancies, including esophageal carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, breast carcinoma [4,[9][10][11]. It has been claimed that p53 Abs may predict a poor prognosis and cancer relapse, may be of some value in monitoring populations at high risk of cancer, may predate the clinical detection of neoplasia and may predict response to treatment.…”

Section: Discussionmentioning

confidence: 99%

The Presence of Serum Anti-p53 Antibodies from Patients with Invasive Ductal Carcinoma of Breast: Correlation to Other Clinical and Biological Parameters

Gao

Bao

Yang

et al. 2005

Breast Cancer Res Treat

View full text Add to dashboard Cite

Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast were involved in this study. The expressions of ER, PR, c-erbB-2 and p53 were immunostained in tumor tissues and serum p53 Abs were assayed using ELISA method. The correlations between p53 Abs and other clinical and biological markers were analyzed. Among 144 patients, 31 (21.5%) had positive p53 Abs, which was associated with several poor prognostic parameters including higher clinical stage (p = 0.0233), lymph nodes metastasis (p = 0.0033), negative ER expression (p = 0.0250) and positive c-erbB-2 status (p = 0.0227). There was also a strong correlation between p53 Abs and tumor p53 positivity (p < 0.0001). These results indicated that the presence of p53 Abs is probably triggered by the accumulation of tumor p53 protein, and it could be a useful marker to complement routine prognostic factors in breast cancer patients.

show abstract

“…Autoantibodies have been detected as early as DCIS 45 , but, again, the association of p53-specific antibodies and tumor stage has shown mixed results. A higher frequency of autoantibodies was observed in late stage breast cancer 43,46 . However, studies in the U.K. and in Sweden found that p53 antibodies did not correlate with disease status [47][48][49] .…”

Section: Autoantibody Detection In Breast Cancer: Clinical Parametersmentioning

confidence: 95%

Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer

et al. 2008

View full text Add to dashboard Cite

There is strong preclinical evidence that cancer, including breast cancer, undergoes immune surveillance. This continual monitoring, by both the innate and the adaptive immune systems, recognizes changes in protein expression, mutation, folding, glycosylation, and degradation. Local immune responses to tumor antigens are amplified in draining lymph nodes, and then enter the systemic circulation. The antibody response to tumor antigens, such as p53 protein, are robust, stable, and easily detected in serum, may exist in greater concentrations than their cognate antigens, and are potential highly specific biomarkers for cancer. However, antibodies have limited sensitivities as single analytes, and differences in protein purification and assay characteristics have limited their clinical application. For example, p53 autoantibodies in the sera are highly specific for cancer patients, but are only detected in the sera of 10-20% of patients with breast cancer. Detection of p53 autoantibodies is dependent on tumor burden, p53 mutation, rapidly decreases with effective therapy, but is relatively independent of breast cancer subtype. Although antibodies to hundreds of other tumor antigens have been identified in the sera of breast cancer patients, very little is known about the specificity and clinical impact of the antibody immune repertoire to breast cancer. Recent advances in proteomic technologies have the potential for rapid identification of immune response signatures for breast cancer diagnosis and monitoring. We have adapted programmable protein microarrays for the specific detection of autoantibodies in breast cancer. Here, we present the first demonstration of the application of programmable protein microarray ELISAs for the rapid identification of breast cancer autoantibodies.

show abstract

Serum p53 antibodies in correlation to other biological parameters of breast cancer

Cited by 22 publications

References 17 publications

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas

The Presence of Serum Anti-p53 Antibodies from Patients with Invasive Ductal Carcinoma of Breast: Correlation to Other Clinical and Biological Parameters

Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer

Contact Info

Product

Resources

About